Bright Minds Biosciences Inc. (DRUG)

Bright Minds Biosciences Income Statement

Financials in millions CAD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Selling, General & Admin	2.15	1.44	2.2	2.55	2.31	0.12
Research & Development	6.72	1.18	5	12.18	6.31	0.35
Operating Expenses	8.61	2.62	7.2	14.73	8.62	0.47
Operating Income	-8.61	-2.62	-7.2	-14.73	-8.62	-0.47
Interest Expense	-0.01	-0.01	-	-	-	-
Interest & Investment Income	1	0.03	-	-	-	-
Currency Exchange Gain (Loss)	-1.11	-0.01	0.01	0.01	0.15	-
Other Non Operating Income (Expenses)	-0.19	-0.2	-0.19	-0.24	-0.18	-0.01
EBT Excluding Unusual Items	-8.92	-2.8	-7.37	-14.96	-8.65	-0.48
Asset Writedown	-	-	-	-0	-	-
Pretax Income	-8.92	-2.8	-7.37	-14.96	-8.65	-0.48
Net Income	-8.92	-2.8	-7.37	-14.96	-8.65	-0.48
Net Income to Common	-8.92	-2.8	-7.37	-14.96	-8.65	-0.48
Shares Outstanding (Basic)	6	4	4	2	2	1
Shares Outstanding (Diluted)	6	4	4	2	2	1
Shares Change (YoY)	49.67%	15.87%	50.58%	37.64%	148.42%	74.24%
EPS (Basic)	-1.44	-0.65	-1.98	-6.06	-4.82	-0.66
EPS (Diluted)	-1.44	-0.65	-1.98	-6.06	-4.82	-0.66
EBIT	-8.61	-2.62	-7.2	-14.73	-8.62	-0.47

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q